Compare Fubotv Inc (FUBO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs TG Therapeutics Inc — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 8× Fubotv Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and TG Therapeutics Inc for 16 Days on average.
| FUBO | TGTX | |
|---|---|---|
Market Cap | $1.02B | $8.16B |
Volume | 978,631 | 1,735,121 |
Sector | Media | Health |
52-Week High | $48.96 | $59.06 |
52-Week Low | $8.09 | $26.94 |
Typical Hold Time | 35 Days | 16 Days |
Enterprise Value | $1.19B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.35, up 1.08% with bearish technical signals but attractive valuation metrics including P/E of 2.43 and P/S of 0.19. The company shows improving financials with revenue growth to $1.62B in 2024 and projected profitability in 2025. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a turnaround opportunity with deep valuation discounts and projected EBITDA growth, though execution risks remain high. The stock offers significant upside to analyst consensus target of $63.38 but faces challenges from persistent cash burn and competitive streaming landscape. Investors should weigh the potential for operational improvements against ongoing financial volatility.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
